1487 PD-1 expression on tumor-infiltrating T-lymphocytes as determinant of the head and neck cancer tumor immune microenvironment rather than anatomical site

Abstract

BackgroundThe response rate to immune checkpoint inhibitors (ICI) targeting programmed cell death 1 (PD-1) receptor is 13–18% for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).1...